MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development Deep Expertise in Dual GLP-1/Glucagon Receptor Agonist Development, Including Pemvidutide CAMBRIDGE,...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


